SCHEMBL23869696

SCHEMBL23869696

CC(C)N1C(=O)c2ccccc2-c2nnn(C(C)(C)C)c2-c2ccccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.38
ALDH1A1 P00352 4/20 0.38
LMNA P02545 4/20 0.38
KDM4E B2RXH2 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
MAPK1 P28482 3/20 0.38
PLIN1 O60240 1/20 0.38
HSP90AA1 P07900 1/20 0.38
PLIN5 Q00G26 1/20 0.38
ABHD5 Q8WTS1 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
RAB9A P51151 1/20 0.36
DHODH Q02127 1/20 0.34
IDO1 P14902 3/20 0.33
TDO2 P48775 3/20 0.33
USP2 O75604 2/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25129809 0.84 TOP2A (0.43) MAPTALDH1A1LMNAKDM4EL3MBTL1
SCHEMBL23869733 0.83 IDO1 (0.33) MAPTSMN1; SMN2DHODHIDO1TDO2
SCHEMBL25969880 0.80 MAPT (0.43) MAPTALDH1A1LMNAKDM4EL3MBTL1
SCHEMBL25132524 0.79 TOP2A (0.43) MAPTALDH1A1LMNAKDM4EL3MBTL1
SCHEMBL16980287 0.79 CHRM2 (0.34) ALDH1A1IDO1TDO2
SCHEMBL23869690 0.78 IDO1 (0.33) MAPTSMN1; SMN2DHODHIDO1TDO2
SCHEMBL25895953 0.77 TDO2 (0.39) MAPTALDH1A1LMNAKDM4EL3MBTL1
SCHEMBL20991255 0.74 TSHR (0.34) MAPTKDM4ESMN1; SMN2NPSR1RAB9A
SCHEMBL14726017 0.72 TDP1 (0.47) MAPTALDH1A1LMNAKDM4EL3MBTL1
SCHEMBL21082154 0.72 NPSR1 (0.33) KDM4ESMN1; SMN2NPSR1RAB9AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210308207-A1 COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY TAGWORKS PHARMACEUTICALS B.V. (NL) 2021-10-07 US disclosed
US-20210299286-A1 TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD TAGWORKS PHARMACEUTICALS B.V. (NL) 2021-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299286-A1 TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD FCER2, SQLE, TTL MAPT 3320/4885ALDH1A1 1600/4885LMNA 4762/4885
US-20210308207-A1 COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY VIP, PIN1, QPCT MAPT 666/4885ALDH1A1 4815/4885LMNA 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.